Dr. Jin-Qiu (Jessie) Chen has 25+ years of advanced experience in therapeutic research, translational medicine, biomarker study and diagnostics development. She is currently the vice president in product and application development of ACRO Biosystems. At this position, Dr. Chen develops strategies, builds resources and strategic partnerships, establishes competitive R&D forces & platforms, and leads cross-functional teams to grow ACRO’s product and business portfolio, as well as continuously promoting technological innovation and commercial applications to establish ACRO as a global leading manufacture in the biomedicine and diagnostic industry.
Before joining ACRO, Dr. Chen established and headed the Collaborative Protein Technology Resource (CPTR) program at the Center of Cancer Research, National Cancer Institute (NCI)/NIH. Collaborated with NCI/NIH investigators and innovative technology vendors, Dr. Chen and her team developed and implemented state-of-the-art molecular-profiling technologies and clinical applicable assays for functional-proteomic investigation, biomarker identification/validation, therapeutic-treatment assessment and applications for precision medicine. She was one of the major players on the early applications of these cutting-edge technologies.
Prior to NIH, Dr, Chen worked many years in biotech industry and contract research organization (CRO) as principal scientist on antibody, diagnostics and bioassay development and validation. She also served as principal investigator in bio-analysis for pharmacokinetic, immunogenicity and toxicology studies in support of IND & NDA applications and clinical trials.
Dr. Chen obtained her BS in Biochemistry from Peking University and Ph.D in Molecular Genetics and Biotechnology from the International Center for Genetic Engineering and Biotechnology (ICGEB, an United Nation organization). She did her postdoctoral research under Dr. Mark Greene at University of Pennsylvania, School of Medicine, studied ErbB receptor signaling in cancer therapeutic and neural development.